Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy

Guanglei Zhuang, Dana M. Brantley-Sieders, David Vaught, Jian Yu, Lu Xie, Sam Wells, Dowdy Jackson, Rebecca Muraoka-Cook, Carlos Arteaga, Jin Chen

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

One arising challenge in the treatment of breast cancer is the development of therapeutic resistance to trastuzumab, an antibody targeting the human epidermal growth factor receptor-2 (HER2), which is frequently amplified in breast cancers. In this study, we provide evidence that elevated level of the receptor tyrosine kinase Eph receptor A2 (EphA2) is an important contributor to trastuzumab resistance. In a screen of a large cohort of human breast cancers, we found that EphA2 overexpression correlated with a decrease in disease-free and overall survival of HER2-overexpressing patients. Trastuzumab-resistant cell lines overexpressed EphA2, whereas inhibiting EphA2 restored sensitivity to trastuzumab treatment in vivo. Notably, trastuzumab treatment could promote EphA2 phosphorylation by activating Src kinase, leading in turn to an amplification of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase signaling in resistant cells. Our findings offer mechanistic insights into the basis for trastuzumab resistance and rationalize strategies to target EphA2 as a tactic to reverse trastuzumab resistance.

Original languageEnglish (US)
Pages (from-to)299-308
Number of pages10
JournalCancer Research
Volume70
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Eph Family Receptors
EphA1 Receptor
varespladib methyl
Breast Neoplasms
Therapeutics
1-Phosphatidylinositol 4-Kinase
src-Family Kinases
Trastuzumab
Mitogen-Activated Protein Kinases
Disease-Free Survival
Phosphorylation
Cell Line
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zhuang, G., Brantley-Sieders, D. M., Vaught, D., Yu, J., Xie, L., Wells, S., ... Chen, J. (2010). Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research, 70(1), 299-308. https://doi.org/10.1158/0008-5472.CAN-09-1845

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. / Zhuang, Guanglei; Brantley-Sieders, Dana M.; Vaught, David; Yu, Jian; Xie, Lu; Wells, Sam; Jackson, Dowdy; Muraoka-Cook, Rebecca; Arteaga, Carlos; Chen, Jin.

In: Cancer Research, Vol. 70, No. 1, 01.01.2010, p. 299-308.

Research output: Contribution to journalArticle

Zhuang, G, Brantley-Sieders, DM, Vaught, D, Yu, J, Xie, L, Wells, S, Jackson, D, Muraoka-Cook, R, Arteaga, C & Chen, J 2010, 'Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy', Cancer Research, vol. 70, no. 1, pp. 299-308. https://doi.org/10.1158/0008-5472.CAN-09-1845
Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research. 2010 Jan 1;70(1):299-308. https://doi.org/10.1158/0008-5472.CAN-09-1845
Zhuang, Guanglei ; Brantley-Sieders, Dana M. ; Vaught, David ; Yu, Jian ; Xie, Lu ; Wells, Sam ; Jackson, Dowdy ; Muraoka-Cook, Rebecca ; Arteaga, Carlos ; Chen, Jin. / Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. In: Cancer Research. 2010 ; Vol. 70, No. 1. pp. 299-308.
@article{f4da8b296edc492c99af30554ca1db4d,
title = "Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy",
abstract = "One arising challenge in the treatment of breast cancer is the development of therapeutic resistance to trastuzumab, an antibody targeting the human epidermal growth factor receptor-2 (HER2), which is frequently amplified in breast cancers. In this study, we provide evidence that elevated level of the receptor tyrosine kinase Eph receptor A2 (EphA2) is an important contributor to trastuzumab resistance. In a screen of a large cohort of human breast cancers, we found that EphA2 overexpression correlated with a decrease in disease-free and overall survival of HER2-overexpressing patients. Trastuzumab-resistant cell lines overexpressed EphA2, whereas inhibiting EphA2 restored sensitivity to trastuzumab treatment in vivo. Notably, trastuzumab treatment could promote EphA2 phosphorylation by activating Src kinase, leading in turn to an amplification of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase signaling in resistant cells. Our findings offer mechanistic insights into the basis for trastuzumab resistance and rationalize strategies to target EphA2 as a tactic to reverse trastuzumab resistance.",
author = "Guanglei Zhuang and Brantley-Sieders, {Dana M.} and David Vaught and Jian Yu and Lu Xie and Sam Wells and Dowdy Jackson and Rebecca Muraoka-Cook and Carlos Arteaga and Jin Chen",
year = "2010",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-09-1845",
language = "English (US)",
volume = "70",
pages = "299--308",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy

AU - Zhuang, Guanglei

AU - Brantley-Sieders, Dana M.

AU - Vaught, David

AU - Yu, Jian

AU - Xie, Lu

AU - Wells, Sam

AU - Jackson, Dowdy

AU - Muraoka-Cook, Rebecca

AU - Arteaga, Carlos

AU - Chen, Jin

PY - 2010/1/1

Y1 - 2010/1/1

N2 - One arising challenge in the treatment of breast cancer is the development of therapeutic resistance to trastuzumab, an antibody targeting the human epidermal growth factor receptor-2 (HER2), which is frequently amplified in breast cancers. In this study, we provide evidence that elevated level of the receptor tyrosine kinase Eph receptor A2 (EphA2) is an important contributor to trastuzumab resistance. In a screen of a large cohort of human breast cancers, we found that EphA2 overexpression correlated with a decrease in disease-free and overall survival of HER2-overexpressing patients. Trastuzumab-resistant cell lines overexpressed EphA2, whereas inhibiting EphA2 restored sensitivity to trastuzumab treatment in vivo. Notably, trastuzumab treatment could promote EphA2 phosphorylation by activating Src kinase, leading in turn to an amplification of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase signaling in resistant cells. Our findings offer mechanistic insights into the basis for trastuzumab resistance and rationalize strategies to target EphA2 as a tactic to reverse trastuzumab resistance.

AB - One arising challenge in the treatment of breast cancer is the development of therapeutic resistance to trastuzumab, an antibody targeting the human epidermal growth factor receptor-2 (HER2), which is frequently amplified in breast cancers. In this study, we provide evidence that elevated level of the receptor tyrosine kinase Eph receptor A2 (EphA2) is an important contributor to trastuzumab resistance. In a screen of a large cohort of human breast cancers, we found that EphA2 overexpression correlated with a decrease in disease-free and overall survival of HER2-overexpressing patients. Trastuzumab-resistant cell lines overexpressed EphA2, whereas inhibiting EphA2 restored sensitivity to trastuzumab treatment in vivo. Notably, trastuzumab treatment could promote EphA2 phosphorylation by activating Src kinase, leading in turn to an amplification of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase signaling in resistant cells. Our findings offer mechanistic insights into the basis for trastuzumab resistance and rationalize strategies to target EphA2 as a tactic to reverse trastuzumab resistance.

UR - http://www.scopus.com/inward/record.url?scp=75149129568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149129568&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-1845

DO - 10.1158/0008-5472.CAN-09-1845

M3 - Article

C2 - 20028874

AN - SCOPUS:75149129568

VL - 70

SP - 299

EP - 308

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -